© 1992 by Oxford University Press
Journal of the National Cancer Institute, Vol. 84, No. 11, 877-882,
June 3, 1992
© 1992 Oxford University Press
Favorable Long-Term Survival Following Induction Chemotherapy With Cisplatin, Fluorouracil, and Leucovorin and Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Cancer
Section of Hematology/Oncology, Department of Medicine, the University of Chicago Pritzker School of Medicine Chicago, III
Department of Radiation and Cellular Oncology, the University of Chicago Pritzker School of Medicine Chicago, III
Section of Otolaryngologyy Head and Neck Surgery, the University of Chicago Pritzker School of Medicine Chicago, III
*Correspondence to: Everett E. Vokes, M.D., Department of Medicine and Radiation Oncology, University of Chicago Medical Center, 5841 S. Maryland Ave., MC2115, Chicago, IL 60637–1470.
Background: The majority of patients with head and neck cancer die of locoregional rescurrence of disease following surgery and/or radiotherapy. Purpose: Our purpose was to administer induction chemotherapy, perform surgery, and administer concomitant chemoradiotherapy in rapid sequence and to evaluate their impact on locoregional and distant tumor control. Methods: Sixty-four patients with previously untreated, Locoregionally advanced head and neck cancer received two cycles of cisplatin, Bleomycin, and methotrexate (PBM) (33 patients) or cisplatin, fluorouracil (5-FU), and leucovorin (PEL) (31patients). PFL was given to patients who were unable to receive bleomycin. Local therapy consisted of surgery and/or concomitant chemoradiotherapy with 5-FU, hydroxyurea, leucovorin, and radiotherapy (FHX-L), all administered every other week. Results: Complete and overall induction response rates were 21% and 79%, respectively, for PBM and 29% and 81%, respectively, for PFL. At completion of local therapy, 81% of the patients were disease-free. With a median follow-up of 35 months, the mddian survival and time to progression are 22 and 17 months, respectively, for PBM and have not been reached for PFL. Locoregional recurrence of disease is 30% for PBM and 26% for PFL. Distant disease progression is 24% for PBM and only 3% for PFL. Conclusions: The sequencing of induction chemotheraphy and concomitant chemoradiotherapy is feasible and results in a high local control rate and in an encouraging survival rate with PFL. The high distant failure (i.e, outside the head and neck area) rate of PBM suggests insufficient systemic activity for that regimen. Implications: Concomitant FHX-L chemoradiotherapy may improve regional control arates of advanced head and neck cancer. Effective systemic therapy may be needed to control systemic micrometastases. PFL, but not PBM, appears to be suitable to accomplish that goal. [J Natl Cancer Inst 84:877–882, 1992]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Qian, M. Nishikawa, A. Md. Haque, M. Hirose, M. Mashimo, E. Sato, and M. Inoue Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1466 - C1475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Posner Paradigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy Oncologist, October 1, 2005; 10(suppl_3): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Licitra, L. D. Locati, R. Cavina, I. Garassino, F. Mattavelli, N. Pizzi, P. Quattrone, P. Valagussa, L. Gianni, G. Bonadonna, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer Ann. Onc., March 1, 2003; 14(3): 367 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Haddad, R. B. Tishler, C. M. Norris, A. Mahadevan, P. Busse, L. Wirth, L. A. Goguen, C. A. Sullivan, R. Costello, M. A. Case, et al. Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment Oncologist, February 1, 2003; 8(1): 35 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hitt, L. Paz-Ares, A. Brandariz, D. Castellano, C. Pena, J. M. Millan, F. Calvo, D. Ortiz de Urbina, E. Lopez, J. J. Alvarez-Vicent, et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial Ann. Onc., October 1, 2002; 13(10): 1665 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. El-Sayed, A. Nabid, W. Shelley, J. Hay, J. Balogh, M. Gelinas, R. MacKenzie, N. Read, E. Berthelet, H. Lau, et al. Prophylaxis of Radiation-Associated Mucositis in Conventionally Treated Patients With Head and Neck Cancer: A Double-Blind, Phase III, Randomized, Controlled Trial Evaluating the Clinical Efficacy of an Antimicrobial Lozenge Using a Validated Mucositis Scoring System J. Clin. Oncol., October 1, 2002; 20(19): 3956 - 3963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Machtay, D. I. Rosenthal, D. Hershock, H. Jones, S. Williamson, M. J. Greenberg, G. S. Weinstein, V. M. Aviles, A. A. Chalian, and R. S. Weber Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial J. Clin. Oncol., October 1, 2002; 20(19): 3964 - 3971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Shin, F. R. Khuri, B. Murphy, A. S. Garden, G. Clayman, M. Francisco, D. Liu, B. S. Glisson, L. Ginsberg, V. Papadimitrakopoulou, et al. Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial J. Clin. Oncol., June 15, 2001; 19(12): 3010 - 3017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Stenson, D. J. Haraf, H. Pelzer, W. Recant, M. S. Kies, R. R. Weichselbaum, and E. E. Vokes The Role of Cervical Lymphadenectomy After Aggressive Concomitant Chemoradiotherapy: The Feasibility of Selective Neck Dissection Arch Otolaryngol Head Neck Surg, August 1, 2000; 126(8): 950 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Vokes, M. S. Kies, D. J. Haraf, K. Stenson, M. List, R. Humerickhouse, M. E. Dolan, H. Pelzer, L. Sulzen, M. E. Witt, et al. Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1652 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Colevas, C. M. Norris, R. B. Tishler, M. P. Fried, H. I. Gomolin, P. Amrein, A. Nixon, C. Lamb, R. Costello, J. Barton, et al. Phase II Trial of Docetaxel, Cisplatin, Fluorouracil, and Leucovorin as Induction for Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., November 1, 1999; 17(11): 3503 - 3511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Pfister, D. Bajorin, R. Motzer, H. Scher, C. Louison, L. Harrison, J. Shah, E. Strong, and G. Bosl Cisplatin, Fluorouracil, and Leucovorin: Increased Toxicity Without Improved Response in Squamous Cell Head and Neck Cancer Arch Otolaryngol Head Neck Surg, January 1, 1994; 120(1): 89 - 95. [Abstract] [PDF]
|
|
|
|
 |
|
 E. E. Vokes, R. R. Weichselbaum, S. M. Lippman, and W. K. Hong Head and Neck Cancer N. Engl. J. Med., January 21, 1993; 328(3): 184 - 194. [Full Text]
|
|